The KBTBD2 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KBTBD2 gene in the HeLa cell background. This product provides a heterogeneous pool of cells harboring targeted gene disruptions, enabling loss-of-function studies without isolating single-cell clones. KBTBD2 encodes a substrate recognition component of the Cullin3-RING E3 ubiquitin ligase complex, and its genetic inactivation in this model facilitates investigation of its roles in ubiquitin-mediated proteolysis and related cellular processes.
HeLa cells are an immortalized epithelial cell line derived from human cervical adenocarcinoma, characterized by HPV18 positivity, aneuploidy, and adherent growth morphology. As one of the most widely employed cell models, HeLa cells have been instrumental in cancer research, cell biology, and virology, particularly for studying cell cycle regulation, viral oncogenesis, and signal transduction. Their robust proliferation and well-characterized molecular landscape make them an ideal host for CRISPR-based knockout studies, providing a physiologically relevant context for exploring gene function.
KBTBD2 functions as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase, mediating the ubiquitination and subsequent proteasomal degradation of specific target proteins. It interacts directly with CUL3 and RBX1, and is predicted to recognize substrates such as actin and other cytoskeletal components, linking ubiquitin signaling to cytoskeletal organization. The mechanistic action of KBTBD2 likely involves the conjugation of ubiquitin chains onto substrates, tagging them for recognition by the 26S proteasome. This process is implicated in the regulation of the NFE2L2/KEAP1 oxidative stress pathway, where ubiquitin-dependent turnover of signaling factors modulates cellular responses. Downstream effects may include alterations in actin dynamics and cell migration, consistent with its proposed role in cytoskeletal remodeling.
In the HeLa cellular environment, KBTBD2 knockout provides a powerful model to dissect the intersection of ubiquitin-proteasome function and cytoskeletal regulation in a cancer-relevant context. HeLa cells exhibit dysregulated protein homeostasis and altered actin dynamics, partly due to HPV oncogene activity. Disrupting KBTBD2 may reveal contributions to cervical carcinoma cell behavior, such as proliferation, adhesion, and invasion. This polyclonal population preserves the natural heterogeneity of CRISPR editing, enabling robust phenotype evaluation while avoiding clonal artifacts. It is particularly suited for studying how ubiquitin ligase substrate adaptors influence oncogenic processes in an HPV-positive background.
Researchers can employ these knockout cells for a broad range of applications, including ubiquitin-proteasome system analysis using Western blotting for ubiquitinated proteins, co-immunoprecipitation to assess CUL3/RBX1 interactions, and proteasome activity assays. Cytoskeletal studies benefit from immunofluorescence with actin staining and migration/invasion assays. Gene expression profiling by RT-qPCR and protein validation by flow cytometry further characterize the knockout phenotype. This product is a valuable reagent for functional genomics, drug target validation, and mechanistic studies in cancer biology. For additional technical details or to discuss your experimental needs, please contact Ascent Research.
